©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
A Movable and Regulable Inactivation Function within the Central Region of a Temperature-sensitive p53 Mutant (*)

(Received for publication, June 29, 1995; and in revised form, August 14, 1995)

Jing-Yuan Chuang (1) (2) Chin-Tarng Lin (1) (2) Cheng-Wen Wu (1) Young-Sun Lin (1)(§)

From the  (1)Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan and (2)Institute of Pathology, College of Medicine, National Taiwan University, Taipei 10010, Taiwan

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

p53 is the most frequently mutated gene in human cancer. Naturally occurring mutations of p53 are mainly located within a region containing residues 100-300 and are predominantly of missense type, resulting in loss of the protein's DNA binding activity. Here we show that this type of mutation also represses the p53 N-terminal activation domain. The repression activity is localized in the central region of mutant p53 containing residues 101-318. Interestingly, the central region of a temperature-sensitive mutant p53N247I possesses a movable and regulable inactivation function. It represses other activities present on the same polypeptide chain without strict regard to the configuration of that polypeptide only at the nonpermissive temperature (37 °C) and not at the permissive temperature (30 °C). Furthermore, this mutant p53 region exhibits no other activity, and its function is independent of endogenous p53 status.


INTRODUCTION

The tumor suppressor p53 protein is an important negative regulator of cell proliferation(1) . Reintroduction of the wild type p53 gene into transformed cells blocks cell proliferation (2) and causes these cells to accumulate in the late G(1) phase of the cell cycle(3) . Loss of p53 function results in genome instability (4, 5) and eliminates growth arrest in response to inadequate or detrimental growth conditions at the G(1) phase(6) . p53 functions as a typical eukaryotic transcription factor; p53 binds to specific DNA sequences termed p53-responsive elements and stimulates transcription of the target genes(7) . Paradoxically, p53 also represses the transcription of many viral and cellular genes that apparently do not have p53-responsive elements(8) . In structure, p53 is organized into three functional domains: an N-terminal region involved in transcriptional activation, a central region mediating specific DNA binding, and a C-terminal region responsible for oligomerization, transcriptional repression, and nonspecific DNA binding(7, 9) . The natural forms ofcancers almost universally contain mutations in the p53 gene. Mostly they are single missense point mutations located within the conserved regions 2-5 of p53 protein, resulting in loss of the protein's specific DNA binding activity(7) .

Conditional mutations such as chimeras between the ligand-binding domain (LBD) (^1)of steroid receptors and non-receptor proteins (for a review, see (10) ) are frequently used to manipulate the activity of proteins and thereby identify their role in various cellular processes. Nonetheless, use of LBD chimeras has at least three disadvantages. First, steroid hormones have receptor-independent activity(11, 12) . Second, the hormone-binding domain possesses transactivation and trans-repression activities(13, 14) . Third, a receptor-free assay system may not always be available. Therefore, a new means of creating conditional mutations would be desirable. Here we demonstrate that the central region (CR) containing residues 101-318 of p53N247I, a temperature-sensitive mutant of the tumor suppressor p53(15) , confers thermal regulability on chimeras between that region and a variety of proteins. Moreover, the CR exhibits no other activity, and its function is independent of endogenous p53 status. These results strongly suggest that the CR can be used as a movable regulatory cassette, a powerful tool for thermal regulation of chimeric proteins.


MATERIALS AND METHODS

Plasmid Constructions

Plasmids pG(5)E1bCAT, pSGVP, pSG424, pL(6)EC, and pLex-VP16 have been previously described(16, 17) . pGAL4-p53(1-318) and pGAL4-p53N247I(1-318) were constructed by inserting wild-type and mutant p53 DNA fragments between the EcoRI and BamHI sites of pSG424, respectively. Likewise, pGAL4VP16-p53(101-318) and pGAL4VP16-CR were constructed by inserting wild-type and mutant p53 DNA fragments between the EcoRI and BamHI sites of pSGVP. pE4CAT was constructed by replacing the HindIII/BamHI fragment of pE1bCAT (17) with a DNA fragment containing the adenovirus E4 sequences -330 to -20 from the transcription initiation site. pE1aCD67 was constructed by replacing the HindIII/EcoRI fragment of pSG424 with a DNA fragment encoding amino acids 1-222 of the adenovirus 13S E1a protein (17) . pE1aCD67-CR was constructed by inserting the EcoRI/BamHI fragment of pGAL4VP16-CR between the EcoRI and BamHI sites of pE1aCD67. pL(6)EP(3)C was constructed as described below. First, the SalI/XbaI fragment of pE1bCAT was replaced with the NdeI/XbaI fragment of pL(6)EC to make pL(6)EC-BSK. Then, three copies of a p53-binding site oligo, 5`-AGCTAGGCATGTCTAGACATGCCT-3`(18) , was inserted into the SmaI site of pL(6)EC-BSK to complete the construction of pL(6)EP(3)C. pp53(51-363) was constructed by replacing the HindIII/BamHI fragment of pSG424 with a DNA segment encoding residues 51-363 of p53 protein.

Transient Transfection and CAT Assay

Saos-2, HeLa, H1299, and HepG2 cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. CHO cells were maintained in McCoy's 5A medium with 10% fetal bovine serum. Unless specified, calcium phosphate-mediated and DEAE-mediated DNA transfections were performed as described(17, 19) , except that 5 µg each of the CAT reporter and activator plasmid was used, and 5 µg of a LacZ reporter plasmid pCH110 (Pharmacia Biotech Inc.) was included to monitor the transfection efficiency. CAT activity was measured and quantified according to Carey et al.(20) . Experiments were repeated three times, and the coefficient of variation (that is, standard deviation divided by mean) of the relative CAT activity was generally below 23% for this work. For temperature-sensitive assays, the incubation temperature was switched to 30 °C after a 12-h transfection at 37 °C.

Western Blotting Analysis

The anti-GAL4 antibody was purchased from UBI, New York. GAL4-p53 chimeras were detected by immunoblotting as described(21, 22) .


RESULTS AND DISCUSSION

To test whether the naturally occurring p53 mutations affect the protein's transactivation function, we measured the transcriptional activity of chimeras between p53 and GAL4 DNA-binding domain. To eliminate complication by p53 C-terminal oligomerization (7) and repression (9, 22) from our study, only residues 1-318 of p53 were fused to the GAL4 DNA-binding domain. Chimera GAL4-p53(1-318) stimulated transcription in transfected Saos-2 cells quite well at 37 °C; in contrast, chimera GAL4-p53N247I(1-318) did not (Fig. 1A, compare lane7 to lane8). Thus, the mutation not only caused p53 to lose its DNA binding activity (7, 15) but repressed, at least in the background of a GAL4 chimera, the p53 N-terminal activation domain. In support, most analogous chimeras between GAL4 and the ``hot spot'' p53 mutants(7) , including mutations at codons 143, 175, 248, 249, and 273, failed to activate transcription. (^2)


Figure 1: p53N247I possesses temperature-sensitive transcriptional inactivation function. A, transactivation of the reporter pG(5)E1bCAT by GAL4-p53 chimeras at 30 °C (lanes 1-4) and at 37 °C (lanes 5-8) in Saos-2 cells by calcium phosphate-mediated DNA transfection. Activator GAL4VP16 (17) was included as a positive control for transactivation (lanes 2 and 6). Diagrams of reporter and activator structures are shown below the autoradiogram. Activator and relative CAT activity (or RCA) are indicated above each track of the autoradiogram. An autoradiogram of a typical experiment is shown. B, expression levels of GAL4-p53 derivatives. The chimeras are the same as in A. The GAL4 derivative is indicated above each track of the immunoblot. Molecular mass markers in kilodaltons are shown on the left. The position of GAL4-p53 derivatives is indicated on the right (arrowhead). Approximately 30 µg of proteins (using bovine serum albumin as a standard) from transfected Saos-2 cells were fractionated on a 10% SDS-PAGE gel. GAL4 derivatives expressed at 30 °C (lanes2 and 3) and at 37 °C (lanes5 and 6) were detected with an anti-GAL4(1-147) antibody.



Since p53N247I is temperature-sensitive as regards DNA binding(7, 15) , we also examined the repression activity at different temperatures. Indeed, when the temperature was shifted from nonpermissive (37 °C) to permissive (30 °C), the repression activity vanished (Fig. 1A, compare lane4 to lane8), indicating that this activity was also temperature-sensitive. Control experiments demonstrated that the two GAL4 chimeras were expressed at similar levels (Fig. 1B) and were localized in the nucleus^2 regardless of the assay temperature.

Next, we defined the region mediating the p53N247I repression activity. As shown in Fig. 2, the region containing residues 101-318 of p53N247I, but not of wild-type p53, conferred thermal regulability on a heterologous activator, GAL4VP16 (23) (panelI, compare lanes7 and 8 to lanes3 and 4). Notably, however, the two chimeric proteins were expressed approximately equally at either assay temperature (data not shown), which, in conjunction with data in Fig. 1B, suggested that fusion of the mutant p53 fragment to a peptide seemed not to affect expression of the resultant chimera. Furthermore, the temperature-sensitive repression activity of the p53 fragment was not restricted to Saos-2 cells. The same phenomenon was observed in CHO (see below) and in HeLa, H1299, and HepG2 cells (Fig. 2, panels II, III, and IV). Thus, we reached three conclusions. First, the thermally regulable inactivation function of p53N247I was confined to a region encompassing residues 101-318 (called the central region or CR). Second, this function of the CR was independent of protein context (Fig. 1A and Fig. 2; also see below). Third, the endogenous p53 status had little influence on the CR's function. For instance, Saos-2 and H1299 cells expressed no p53 protein, whereas HeLa and HepG2 cells, although containing the wild-type p53 gene, differed dramatically in p53 protein level(5, 24) . However, the CR's function was similar in all four cell lines (Fig. 2).


Figure 2: The temperature-sensitive inactivation function of p53N247I is movable and located in the CR ranging from residues 101 to 318 of the protein. Transactivation of the reporter pG(5)E1bCAT by GAL4 derivatives is shown. Procedures were as described in Fig. 1A, except that activators are GAL4VP16-p53 derivatives and that diagrams of their structures are shown below the autoradiogram. Data were collected at 30 °C (lanes1-4) or at 37 °C (lanes 5-8) from Saos-2 (panel I), HeLa (panel II), H1299 (panel III), and HepG2 (panel IV) cells. RCA, relative CAT activity.



All studies described above used GAL4 derivatives. To test the generality of the CR's inactivation function we fused it to a totally unrelated protein, the adenovirus 13S E1a protein, which exerts complex regulatory effects on various viral and cellular promoters, such as the adenovirus E4 promoter(25) . As shown in Fig. 3, E1aCD67 (26) , an E1a derivative, stimulated E4 transcription at either temperature (compare lanes1 and 2 to lanes4 and 5) in CHO cells. Remarkably, the chimeric protein, E1aCD67-CR, stimulated transcription in a completely temperature-dependent manner (compare lanes1 and 3 to lanes4 and 6). Thus, these results parallel those obtained with GAL4VP16-CR and demonstrate that the transactivation activity of E1aCD67 can be thermally repressed by fusing E1aCD67 to the CR.


Figure 3: The CR confers thermal regulation to the adenovirus E1a protein. Transactivation of reporter pE4CAT by adenovirus E1a derivatives at 30 °C (lanes 1-3) and at 37 °C (lanes 4-6) is shown. Basal E4 promoter activity consistently was relatively higher at 30 °C than at 37 °C, which resulted in the low stimulation of E4 promoter by E1a derivatives at 30 °C (compare lanes1 and 2 to lanes4 and 5). The 13S E1a contains 289 amino acids, but a deletion mutant lacking 67 C-terminal residues (E1aCD67) can nevertheless stimulate transcription(26) . The CR was fused C-terminally to E1aCD67; E1a-CR was tested by transient expression assays performed as described in Fig. 1A, except that CHO cells were recipients for DEAE-mediated DNA transfection and that the reporter was pE4CAT. RCA, relative CAT activity.



Results obtained with GAL4VP16-CR and E1aCD67-CR are consistent with our hypothesis that the CR temperature sensitively represses other activities present on the same polypeptide chain without strict regard to the configuration of that polypeptide. Nonetheless, ideally to provide a movable and regulable inactivation function, the CR should have as few other activities as possible. Therefore, the binding of a wild-type p53 fragment containing residues 102-292 to DNA in vitro(27) seems to pose a concern about the CR as an optimal approach to creating conditional mutants. Accordingly, we determined whether the CR within a chimera possesses DNA binding activity. In this assay, p53 binding sites (or PBS hereafter) were placed immediately downstream of the reporter's TATA box. Thus, binding of p53 derivatives would block assembly of the transcription initiation complex on the promoter and therefore reduce CAT activity. p53(51-363), a derivative providing only p53 DNA binding activity (7, 9) but not GAL4VP16-CR, reduced transcription of the reporter containing PBS at 30 °C (Fig. 4, compare lane3 to lane4). The reduction was specific because transcription of a corresponding reporter lacking PBS was not affected (Fig. 4, compare lanes2 and 3 to lanes7 and 8). Thus, in the context of a chimera the CR showed no detectable affinity to PBS. Besides, the inability to bind PBS was not a peculiarity of GAL4VP16-CR, since another chimera, E1aCD67-CR, was also unable to bind PBS (Fig. 4, compare lane3 to lane5).


Figure 4: The CR does not bind DNA at the permissive temperature. One microgram of the illustrated reporter DNA, 1 µg of the activator DNA, and 13 µg of the specified blocker DNA were used for calcium phosphate-mediated DNA transfection. To prevent the N-terminal activation activity (7) and the C-terminal inactivation activity (9, 22) of p53 from interfering with our study, a p53 derivative, p53(51-363), which contains residues 51-363 of human p53, was used as a positive control for blocking. Cells were harvested 36 h after transfection. The absence(-) or presence (+) of activator is indicated above each track of the autoradiogram, as are blocker and relative CAT activity (or RCA). The reporter was pL(6)EP(3)C (lanes 1-5) or pL(6)EC (lanes 6-10). Diagrams of the structure of activator, reporters, and blockers are shown below the autoradiogram.



We have demonstrated that the CR possesses a movable and thermally regulable inactivation function toward several distinct proteins. Interestingly, among human temperature-sensitive p53 mutants(15) , p53N247I is unique in having a CR endowed with such a function. (^3)How does the CR regulate other activities present on the same polypeptide chain? We speculate that the conformational state of the CR may play a role, since the codon 247 mutation is located within the p53 conformation-sensitive region(7) . It is possible that within a chimera the change of CR's conformation could propagate to the neighboring region. This could account for loss of function of the chimera. Alternatively, the change of CR's conformation facilitates the protein's interaction with some other protein which, as illustrated by the interaction between LBD and heat shock protein 90(10) , inactivates the chimera by steric hindrance. Further studies are required to distinguish these hypotheses.

It was puzzling to observe that the CR failed to bind DNA (Fig. 4) at the permissive temperature where the CR is supposed to assume the DNA binding conformation of p53. Perhaps this discrepancy reflects two aspects. First, p53N247I, from which the CR is derived, retains a small percentage of p53's transactivation activity at 30 °C, apparently due to its low DNA binding affinity(15) . Second, the protein concentrations (p53 versus CR) required for DNA binding may differ. If, as seems likely, the oligomerization domain within the context of p53 helps the CR to bind DNA, then the CR alone would need to be expressed to a higher concentration than that achievable in vivo to drive the protein-DNA interaction.


FOOTNOTES

*
This work was supported by grants from the Academia Sinica and the National Science Council of Taiwan (to C.-T. L., C.-W. W., and Y.-S. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 886-2-7899133; Fax: 886-2-7853569.

(^1)
The abbreviations used are: LBD, ligand-binding domain; CR, central region; CHO, Chinese hamster ovary; CAT, chloramphenicol acetyltransferase; PBS, p53 binding site(s).

(^2)
J.-Y. Chuang, C.-T. Lin, C.-W. Wu, and Y.-S. Lin, unpublished results.

(^3)
J.-Y. Chuang, C.-T. Lin, C.-W. Wu, and Y.-S. Lin, unpublished data.


ACKNOWLEDGEMENTS

We would like to acknowledge Dr. J. Y. Chen for the p53N247I clone. We thank Drs. C. Fletcher, J. Yen, H. F. Yang-Yen, and K. King and Ms. J. Sugden for comments.


REFERENCES

  1. Finlay, C. A., Hinds, P. W., and Levine, A. J. (1989) Cell 57,1083-1093 [Medline] [Order article via Infotrieve]
  2. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. (1990) Science 249,912-915 [Medline] [Order article via Infotrieve]
  3. Michalovitz, D., Halevy, O., and Oren, M. (1990) Cell 62,671-680 [Medline] [Order article via Infotrieve]
  4. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. (1992) Cell 70,937-948 [Medline] [Order article via Infotrieve]
  5. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. (1992) Cell 70,923-935 [Medline] [Order article via Infotrieve]
  6. Kastan, M. B., Zhan, Q., el-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. (1992) Cell 71,587-597 [Medline] [Order article via Infotrieve]
  7. Prives, C., and Manfredi, J. J. (1993) Genes & Dev. 7,529-534
  8. Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,9979-9983 [Abstract]
  9. Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R., and Shenk, T. (1995) Mol. Cell. Biol. 15,227-234 [Abstract]
  10. Mattioni, T., Louvion, J. F., and Picard, D. (1994) Methods Cell Biol. 43,335-352 [Medline] [Order article via Infotrieve]
  11. Hardy, S. P., and Valverde, M. A. (1994) FASEB J. 8,760-765 [Abstract/Free Full Text]
  12. Aronica, S. M., Kraus, W. L., and Katzenellenbogen, B. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,8517-8521 [Abstract]
  13. Tsai, M. J., and Omalley, B. W. (1994) Annu. Rev. Biochem. 63,451-486 [CrossRef][Medline] [Order article via Infotrieve]
  14. Schuermann, M., Hennig, G., and Muller, R. (1993) Oncogene 8,2781-2790 [Medline] [Order article via Infotrieve]
  15. Chen, J. Y., Funk, W. D., Wright, W. E., Shay, J. W., and Minna, J. D. (1993) Oncogene 8,2159-2166 [Medline] [Order article via Infotrieve]
  16. Martin, K. J., Lillie, J. W., and Green, M. R. (1990) Nature 346,147-152 [CrossRef][Medline] [Order article via Infotrieve]
  17. Lillie, J. W., and Green, M. R. (1989) Nature 338,39-44 [CrossRef][Medline] [Order article via Infotrieve]
  18. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1,45-49 [Medline] [Order article via Infotrieve]
  19. Lin, Y. S., and Green, M. R. (1989) Nature 340,656-659 [CrossRef][Medline] [Order article via Infotrieve]
  20. Carey, M., Lin, Y. S., Green, M. R., and Ptashne, M. (1990) Nature 345,361-364 [CrossRef][Medline] [Order article via Infotrieve]
  21. Lin, Y. S., Ha, I., Maldonado, E., Reinberg, D., and Green, M. R. (1991) Nature 353,569-571 [CrossRef][Medline] [Order article via Infotrieve]
  22. Hsu, Y. S., Tang, F. M., Liu, W. L., Chuang, J. Y., Lai, M. Y., and Lin, Y. S. (1995) J. Biol. Chem. 270,6966-6974 [Abstract/Free Full Text]
  23. Sadowski, I., Ma, J., Triezenberg, S., and Ptashne, M. (1988) Nature 335,563-564 [CrossRef][Medline] [Order article via Infotrieve]
  24. Hay, R. J., Park, J. G., and Gazdar, A. (1994) Atlas of Human Tumor Cell Lines , Academic Press, Inc., San Diego
  25. Liu, F., and Green, M. R. (1990) Cell 61,1217-1224 [Medline] [Order article via Infotrieve]
  26. Picard, D., Salser, S. J., and Yamamoto, K. R. (1988) Cell 54,1073-1080 [Medline] [Order article via Infotrieve]
  27. Pavletich, N. P., Chambers, K. A., and Pabo, C. O. (1993) Genes & Dev. 7,2556-2564

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.